Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEMENT-MDS
CTR20240264Phase 3Active
- Sponsor
- Celgene Corporation
- Start
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of luspatercept, epoetin alfa in myelodysplastic syndrome (MDS), anaemia, sponsored by Celgene Corporation. Started Nov 2023; status: active.
02
Drugs
luspaterceptepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)anaemia
Beyond the preview
Go deeper on CTR20240264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240264.